Author

S. Caruso

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Organism:mouse· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

J. Zucman-Rossi· 3 shared A. Camasses· 1 shared A. Gagliardi· 1 shared A. Gougelet· 1 shared A. Loriot· 1 shared A. Lozano· 1 shared A. Marra· 1 shared B. Bigerna· 1 shared

Activity by Year

2018-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 13 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

J. Zucman-Rossi

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML

G. Pianigiani, A. Gagliardi, F. Mezzasoma, F. Rocchio, V. Tini, B. Bigerna, P. Sportoletti, S. Caruso, A. Marra, G. Spinozzi, S. Shacham, Y. Landesman, C. Quintarelli, F. Locatelli, M. P. Martelli, , L. Brunetti

This study shows that prolonged XPO1 inhibition is more effective than intermittent dosing in NPM1-mutated AML by achieving stable HOX downregulation and anti-leukemic activity.

bioRxiv · Dec 11, 2021 · PreprintCancer Biology

Deleting in vivo β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumors

R. Loesch, S. Caruso, V. Paradis, C. Godard, A. Gougelet, S. Picard, C. Perret, M. M. M. Taketo, J. Zucman-Rossi, S. Colnot

This study compares two mouse models of β-catenin pathway activation, showing they generate tumors similar to human hepatocellular carcinomas and hepatoblastomas.

bioRxiv · Jul 4, 2021 · PreprintCancer Biology

CDK8 and CDK19 kinases have non-redundant oncogenic functions in hepatocellular carcinoma

K. Bacevic, S. Prieto, S. Caruso, A. Camasses, G. Dubra, J. Ursic-Bedoya, A. Lozano, J. Butterworth, J. Zucman-rossi, U. Hibner, D. Fisher, D. Gregoire

The paper investigates the roles of CDK8 and CDK19 in hepatocellular carcinoma, finding they are overexpressed and have non-redundant oncogenic functions that interact with TP53.

bioRxiv · Oct 1, 2019 · PreprintCancer Biology

Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma

C. Gerard, M. Di-Luoffo, L. Gonay, S. Caruso, G. Couchy, A. Loriot, J. Tao, K. Konobrocka, S. Cordi, S. P. Monga, E. Hanert, J. Zucman-Rossi, F. P. Lemaigre

The paper identifies and models a gene regulatory network linking LIN28B-dependent dedifferentiation with CTNNB1 dysfunction in HCC, predicting drug response and cell state dynamics.

bioRxiv · Jun 15, 2018Cancer Biology